000 01457 a2200421 4500
005 20250518000518.0
264 0 _c20190924
008 201909s 0 0 eng d
022 _a2056-676X
024 7 _a10.1038/s41572-018-0023-6
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aBalint, Bettina
245 0 0 _aDystonia.
_h[electronic resource]
260 _bNature reviews. Disease primers
_c09 2018
300 _a25 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650 0 4 _aBaclofen
_xtherapeutic use
650 0 4 _aBasal Ganglia
_xanatomy & histology
650 0 4 _aBotulinum Toxins, Type A
_xtherapeutic use
650 0 4 _aDopamine Agents
650 0 4 _aDystonia
_xclassification
650 0 4 _aDystonic Disorders
_xcongenital
650 0 4 _aGABA-B Receptor Agonists
_xtherapeutic use
650 0 4 _aGTP Cyclohydrolase
_xgenetics
650 0 4 _aHumans
650 0 4 _aLevodopa
_xtherapeutic use
650 0 4 _aNeuromuscular Agents
_xtherapeutic use
650 0 4 _aQuality of Life
700 1 _aMencacci, Niccolò E
700 1 _aValente, Enza Maria
700 1 _aPisani, Antonio
700 1 _aRothwell, John
700 1 _aJankovic, Joseph
700 1 _aVidailhet, Marie
700 1 _aBhatia, Kailash P
773 0 _tNature reviews. Disease primers
_gvol. 4
_gno. 1
_gp. 25
856 4 0 _uhttps://doi.org/10.1038/s41572-018-0023-6
_zAvailable from publisher's website
999 _c28857241
_d28857241